27 April 2020 | Views
Anu Acharya, CEO, Mapmygenome, Hyderabad talks about how her company is contributing towards fighting COVID-19
"Mapmygenome announces the launch of a new product Genomepatri™ Immunity. It contains genetic risk factors for an array of immune system diseases along with some lifestyle diseases. The Genomepatri Immunity report is a result of extensive hours of hard work put in by our expert team. While this is not a diagnostic test, we see its tremendous potential in prevention and improving patient outcomes. A good immune response is key in defeating COVID-19. Genomepatri Immunity is intended to enable us to strengthen ourselves and fight COVID-19 and other diseases better. The report also covers how we respond to drugs that may be used during treatment and that will be very useful to treating physicians.”
- Anu Acharya, CEO, Mapmygenome, Hyderabad